Protocol No.: EA2192

APOLLO: A Randomized Phase II Double-Blind Study of Olaparib versus Placebo Following Curative Intent Therapy in Patients with Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2, or PALB2 Mutation
Principal Investigator
Daboul, Nour
Phase
II
Age Group
Adult
Applicable Disease Site
Gastrointestinal Cancers
Participating Institution
Mary Babb Randolph Cancer Center
Contact
Sabrina Rexroad, RN
Research Nurse
Phone: +1 304-293-6066

View on ClinicalTrials.gov